Peptide questions FAQ

Use the peptide only if the exposure was a single event and the total duration was under 24 hours. Reconstituted GHRP-2 acetate at room temperature (20–25°C) undergoes accelerated degradation. The half-life of peptide bond stability drops from approximately 40 days at 4°C to roughly 8 days at 25°C. A single 12-hour excursion reduces purity by an estimated 2–4%, which remains within acceptable variance for most research protocols. Repeated or prolonged room-temperature exposure is cumulative. Three separate 8-hour excursions cause equivalent degradation to continuous 24-hour exposure and should prompt vial replacement.

Discard the vial immediately and do not administer. Cloudiness or visible particles indicate peptide aggregation. A process where individual peptide molecules cluster into insoluble complexes that cannot bind GHS-R1a receptors. Aggregation occurs from thermal shock (injecting cold water into a frozen peptide), vigorous shaking during reconstitution, or contamination with endotoxins from non-sterile bacteriostatic water. Aggregated peptides not only lack bioactivity but may trigger immune responses in research animals that confound experimental outcomes. Properly reconstituted GHRP-2 acetate is crystal clear with no visible turbidity.

GRHP-2 acetate maintains receptor responsiveness under this schedule without significant tachyphylaxis. Unlike hexarelin, which desensitises GHS-R1a receptors by 40–50% after 5 days of continuous stimulation, GHRP-2 retains 80–85% of initial GH response amplitude through 14-day protocols with dosing intervals as short as 3 hours. The primary limitation is not receptor desensitisation but rather depletion of releasable GH stores in somatotroph secretory granules. After 48–72 hours of repeated stimulation, baseline GH synthesis must catch up to secretion demand, which may attenuate response magnitude by 10–20%. Including a 12-hour washout period every 48 hours allows granule replenishment and sustains response consistency across longer protocols.

Combining GHRP-2 with GHRH analogs like sermorelin or CJC-1295 produces synergistic GH secretion. Total GH release exceeds the additive effect of either peptide administered alone by 30–50%. The mechanism is complementary receptor activation: GHRP-2 acts on GHS-R1a while GHRH binds growth hormone releasing hormone receptors (GHRHR), and simultaneous occupancy of both receptors amplifies the calcium mobilisation and cAMP pathways that drive GH vesicle exocytosis. Dose both peptides at the lower end of their respective ranges (GHRP-2 at 1 mcg/kg, GHRH analog at 10–30 mcg/kg) to avoid ceiling effects and maintain dose-response linearity.

Space administrations at least 4–6 hours apart to allow GH levels to return to baseline between pulses. Hexarelin's 70-minute half-life means plasma concentrations drop below threshold within 3–4 hours, but pituitary somatotroph recovery requires 4–6 hours before next maximal response. Twice-daily dosing (morning fasted, evening pre-sleep) represents the upper frequency limit before diminishing returns. Three or more daily administrations increase cortisol and prolactin without proportional GH elevation due to receptor saturation.

Discard the vial. Peptides stored at room temperature (22–25°C) for 8–12 hours lose 15–20% potency through His and Trp residue oxidation. There is no visual indicator of degradation. The solution remains clear even after peptide bonds have cleaved. Research outcomes using degraded peptide will show blunted or absent GH response, making data interpretation impossible. Temperature abuse cannot be reversed.

Allow the vial to sit undisturbed for 10–15 minutes after adding bacteriostatic water. If particulate remains, gently roll the vial between palms. Never shake, which introduces shear forces that denature peptide structure. Persistent cloudiness or visible aggregates indicate manufacturing defects or temperature damage during shipping. Real Peptides replaces any vial showing aggregation or incomplete dissolution. Contact our research support team with lot number and photographic documentation.

Contact your peptide supplier immediately for replacement or credit. Research-grade peptides should meet ≥95% purity by HPLC as a baseline standard. Lower purity means your calculated concentrations are incorrect: if you assume 5mg peptide content but the vial contains 4mg active compound plus 1mg truncation products and salts, every dose is 20% lower than intended. This single variable explains more failed replications in peptide research than any other factor. At Real Peptides, every batch includes third-party verified HPLC and mass spectrometry analysis, and we guarantee stated purity or provide immediate replacement. Never proceed with a study using unverified or low-purity material. The time lost to a failed protocol vastly exceeds the cost of replacement peptide.

Start with the research question. If your study specifically investigates HGF/c-Met signaling pathways in neurological conditions, dihexa is irreplaceable. No other orally bioavailable compound targets this mechanism. If you're conducting exploratory cognitive enhancement research without a specific pathway focus, established compounds like Semax Amidate or Cerebrolysin offer broader literature support, more characterized stability profiles, and typically lower per-dose cost due to larger required doses allowing simpler preparation. Dihexa's extreme potency means per-milligram cost is deceptive. 5mg dihexa may provide 50–100 doses depending on model species and route, making cost-per-dose competitive despite higher unit price.

Concentration verification and vehicle standardization are the first two variables to audit. Draw a sample from your working stock and submit for HPLC analysis. Degraded peptide won't show in appearance or pH testing. If concentration matches specifications, examine vehicle consistency: are you preparing fresh vehicle each session or using a stock solution that may be aging? DMSO absorbs water from air, diluting concentration over time; PEG 400 viscosity changes with temperature, affecting pipetting accuracy. The third variable: gavage technique. Oral administration requires consistent delivery to the stomach, not aspiration into lungs or leakage around the gavage needle. Variability in technique between research staff creates dose variability that overwhelms treatment effects. Film and compare techniques across all staff members.

Discard the solution immediately. Visible particulate matter indicates aggregation or contamination that compromises both sterility and molecular integrity. Peptide aggregation occurs when hydrophobic regions of partially unfolded molecules interact, forming insoluble clusters that cannot pass through membrane filters and will not exhibit the intended pharmacological activity. This most commonly results from: reconstitution at incorrect pH (dihexa is most stable near neutral pH 6.5–7.5), bacterial contamination introducing proteases that cleave peptide bonds, or repeated freeze-thaw cycles that disrupt tertiary structure. Prevention: use sterile technique during all handling, store at appropriate temperatures, and prepare fresh aliquots rather than repeatedly freezing the same vial.

Discard the solution immediately. Visible particles indicate peptide aggregation or microbial contamination, both of which invalidate experimental use. Cloudiness can result from reconstitution at incorrect pH (check bacteriostatic water lot for pH specification), contamination during needle insertion, or peptide precipitation due to high concentration. Prepare a fresh aliquot using sterile technique: swab the vial stopper with 70% isopropanol, use a new sterile needle, and inject bacteriostatic water slowly to minimize foaming. If cloudiness recurs, the lyophilised peptide may have been compromised during shipping or storage. Contact your supplier for lot verification and replacement.

Assume partial degradation has occurred. Peptide solutions stored above 8°C for extended periods (more than 4–6 hours) show measurable loss of receptor-binding affinity due to oxidation and proteolytic cleavage. Continuing to use the solution risks introducing concentration variability that confounds dose-response data and reduces experimental reproducibility. Prepare a fresh aliquot from lyophilised stock stored at −20°C. If your experimental timeline is tight and no backup aliquots exist, document the temperature excursion in your protocol notes and consider running parallel controls with fresh peptide to quantify any effect-size differences.

Maintain cold chain integrity throughout transport. Use an insulated container with gel ice packs pre-chilled to 2–8°C and monitor internal temperature with a data logger if transport duration exceeds one hour. Peptide solutions tolerate brief temperature fluctuations (up to 25°C for under 30 minutes) but extended exposure accelerates degradation. For distances requiring more than two hours of transport, consider shipping lyophilised peptide instead and reconstituting on-site to eliminate temperature excursion risk. If reconstituted solution is the only option, transport in a cryovial sealed with parafilm to prevent leakage, cushioned to avoid mechanical agitation, and delivered directly to refrigerated storage upon arrival.

Request a certificate of analysis (COA) from your peptide supplier before placing the order. Reputable suppliers provide third-party endotoxin testing results per batch, typically showing levels below 1 EU/mg for research-grade peptides. Real Peptides includes endotoxin testing documentation with every VIP vial, eliminating the need for redundant in-house testing. If your IACUC protocol mandates independent verification, commercial endotoxin assay kits (LAL or recombinant Factor C assays) can test reconstituted solutions within 2–3 hours. Prepare a sample diluted to the assay's linear range (typically 0.1–1.0 EU/mL) and follow manufacturer protocols. Endotoxin contamination above acceptable thresholds indicates compromised sterility. Do not use the peptide for in vivo work.